The published evidence base includes STEP (semaglutide for weight management, The New England Journal of Medicine , 2021), SURMOUNT (tirzepatide for weight management, NEJM 2022), and SURMOUNT-OSA (tirzepatide for obstructive sleep apnea, NEJM 2024)
de bijbehorende resultaten staan onder labresultaten
Convenience and Lifestyle Prefer no needles
Additional areas of investigation Researchers are also studying semaglutide in obstructive sleep apnea (where weight loss significantly improves symptoms), heart failure with preserved ejection fraction (HFpEF), peripheral artery disease, polycystic ovary syndrome, and even addiction disorders
10.1111/jcpt.13076 70 HillZ.McCartyP
Sleep quality affects appetite hormones and insulin regulation